Home » Topics » Regulatory » EMA

EMA
RSS

CHMP recommends approval of Sycrest for bipolar disorder

June 29, 2010

CHMP recommends approval of Shire's VPRIV for type 1 GD

June 29, 2010

Pharmaxis reports on second phase III trial of Bronchitol in CF

June 23, 2010

EC grants orphan status to pralatrexate for cutaneous T-cell lymphoma

June 21, 2010

OBI-1 obtains positive opinion for orphan drug status in Europe

June 18, 2010

EMA approves update to bortezomib label for multiple myeloma

June 17, 2010

COMP recommends orphan drug status for 2B3-101 in glioma

June 16, 2010

EMA's COMP recommends orphan status for DR Cysteamine in cystinosis

June 16, 2010

European Commission extends indication of RoActemra

June 10, 2010

Sunesis receives scientific advice from EMA on voreloxin program

June 3, 2010

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...